Related Experiment Video
Updated: Mar 21, 2026
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
15.1K
Stereotactic Body Radiotherapy for Spinal Metastases: Outcomes and Development of a Risk Assessment Score to Predict
Suchet Taori1, Samuel Adida1, Shovan Bhatia1
1School of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Neurosurgery
|March 20, 2026
Summary
Stereotactic body radiotherapy (SBRT) effectively controls spinal metastases with good pain response. A new risk score predicts local tumor progression, aiding personalized treatment for spinal tumors.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Physics
Background:
- Stereotactic body radiotherapy (SBRT) is a key treatment for spinal metastases.
- Limited data exists on clinical outcomes and progression risk factors.
- This study addresses the need for robust evidence and predictive tools.
Purpose of the Study:
- Evaluate local tumor control, adverse effects, pain response, and survival after SBRT for spinal metastases.
- Develop a predictive tool for local tumor progression (LTP) to personalize patient management.
Main Methods:
- Analysis of 936 SBRT treatments in 600 patients with spinal metastases (2001-2024).
- Inclusion of single-fraction and multifraction SBRT regimens.
- Development of a machine learning-based LTP risk scoring system.
Main Results:
- 1-year and 3-year local tumor control rates were 84.2% and 75.1%.
- An LTP risk score (0-15) identified low (2.4%), intermediate (10.2%), and high (35.5%) risk groups.
- High rates of pain response (94.4% at 1 month) and acceptable adverse radiation effects (12.6%).
Conclusions:
- SBRT is a safe and effective treatment for spinal metastases.
- The developed risk stratification tool can guide patient selection and optimize treatment outcomes.
- Further research can refine personalized management strategies for spinal tumors.
